Endocrine Abstracts

Background: Peptide receptor radionuclide therapy (PRRT) including Lutetium177 (Lu177) has changed the treatment landscape of metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). There is a subgroup of patients who are resistant or develop resistance after initial success to PRRT, indicating that accurate predictive markers are urgently needed to identify who will benefit from PRRT. We hypothesize that expression of ATRX (Alpha Thalassemia and Mental Retardation...